- Topline results of NCX470 Mont-Blanc stage 3 glaucoma study due In early November 2022
- Third quarter of 2022 US Prriptions for VYZULTA® increased by 37% compared to the third quarter of 2021
- net sales €0.8 millions for third quarter 2022; Cash of €25.6 million in September 30th, 2022
October 19, 2022 – Release at 7:30am BST
Sophia Antipolis, France
Nicox S.A FR COX))), an international eye care company, today announced third quarter 2022 financial and business highlights for Nicox SA and its subsidiaries (the “Nicox Group”) and confirmed the timeline for the upcoming milestone Phase 3 clinical trial with NCX 470 Mont Blanc.
button forthcoming MStone
- Mont Blanc Phase 3 clinical trial evaluating NCX 470 in patients with open-angle glaucoma or ocular hypertension: Topline results are due in early November 2022
third Quarter 2022 Financial highlights
As of September 30, 2022, Nicox Group had cash and cash equivalents of €25.6 million compared to €42.0 million as of December 31, 2021 and €31.6 million as of June 30, 2022. The company estimates that it is funded through October 31, 2023 and through November 30, 2023 assuming the extension of the interest-only period of existing Kreos debt1, in both cases based on the development of NCX 470 alone. net sales2 for the third quarter of 2022 was EUR 0.8 million (consisting solely of net royalties). This compares to net sales for the third quarter of 2021 of EUR 2.4 million (including EUR 0.7 million in net royalties and EUR 1.7 million in royalties).
As of September 30, 2022, Nicox Group had financial debt of €20.6 million, consisting of €18.6 million in the form of a bond financing agreement with Kreos Capital signed in January 2019 and a €2 million loan agreement guaranteed by the French State Euro August 2020 in the context of the COVID-19 pandemic.
third quarter of 2022 business highlights
- The last patient has…
